CSPC Pharmaceutical (1093.HK): Focus on the Ascending Triangle

CSPC Pharmaceutical (1093), a drug maker, announced that 1Q net income rose 21.8% on year to 1.16 billion yuan and operating profit grew 0.6% to 1.16 billion yuan on revenue of 6.13 billion yuan, up 11.5%.

Charts (2)

CSPC Pharmaceutical (1093), a drug maker, announced that 1Q net income rose 21.8% on year to 1.16 billion yuan and operating profit grew 0.6% to 1.16 billion yuan on revenue of 6.13 billion yuan, up 11.5%.

After the announcement of 1Q result, the stock jumped 6%. However, the stock failed to close above the April high at HK$17.20. Currently, the stock eased around 3%.


Source: GAIN Capital, TradingView

On a daily chart, the stock remains trading within the ascending triangle. A upside breakout could mean the bullish reversal signal. Otherwise, A break below the rising trend line could signal a continuation of the previous down trend.

In fact, both 20-day and 50-day moving averages are flattening. The RSI is capped by a resistance level at 59, but supported by a rising trend line at same time. Both indicators would suggest the lack of momentum for the prices.

In this case, the reader should consider a neutral bias and focus on the breakout signal in the future. 

A clear break above HK$17.20 (the high of April) could consider a rise to the next resistance level at HK$19.26 (the high of March.

In an alternative scenario, crossing below HK$15.00 (the previous low) might bring a return to $13.12 (the low of March).

More from Equities

Disclaimer: The information on this web site is not targeted at the general public of any particular country. It is not intended for distribution to residents in any country where such distribution or use would contravene any local law or regulatory requirement. The information and opinions in this report are for general information use only and are not intended as an offer or solicitation with respect to the purchase or sale of any currency or CFD contract. All opinions and information contained in this report are subject to change without notice. This report has been prepared without regard to the specific investment objectives, financial situation and needs of any particular recipient. Any references to historical price movements or levels is informational based on our analysis and we do not represent or warranty that any such movements or levels are likely to reoccur in the future. While the information contained herein was obtained from sources believed to be reliable, author does not guarantee its accuracy or completeness, nor does author assume any liability for any direct, indirect or consequential loss that may result from the reliance by any person upon any such information or opinions.

Futures, Options on Futures, Foreign Exchange and other leveraged products involves significant risk of loss and is not suitable for all investors. Losses can exceed your deposits. Increasing leverage increases risk. Spot Gold and Silver contracts are not subject to regulation under the U.S. Commodity Exchange Act. Contracts for Difference (CFDs) are not available for US residents. Before deciding to trade forex and commodity futures, you should carefully consider your financial objectives, level of experience and risk appetite. Any opinions, news, research, analyses, prices or other information contained herein is intended as general information about the subject matter covered and is provided with the understanding that we do not provide any investment, legal, or tax advice. You should consult with appropriate counsel or other advisors on all investment, legal, or tax matters. References to Forex.com or GAIN Capital refer to GAIN Capital Holdings Inc. and its subsidiaries. Please read Characteristics and Risks of Standardized Options.